Back to Feed
ClinicalTrials.gov|Clinical Trial
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
Abstract
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response Phase: PHASE2 Status: RECRUITING Conditions: T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma Interventions: WU-CART-007
Keywords
T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma